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In a  previous communication (1)  the occurrence of cutaneous re- 
actions to the polysaccharides and proteins of Pneumococcus during 
lobar  pneumonia  was  reported.  The  investigation  disclosed  the 
interesting fact that the capsular carbohydrates of Pneumococcus were 
capable  of  inciting  a  reaction  when  injected  intradermally.  The 
character of  the  response  and  the  conditions  under  which  it  was 
obtained are briefly summarized as follows: The characteristic reaction 
is the development of an immediate wheal and erythema at the site of 
injection; a positive reaction was first elicited at or about the time of 
crisis; it was produced only by the polysaccharide homologous in type 
to that of the Pneumococcus causing the disease; at the time of reac- 
tion  type-specific  antibodies  for  the  homologous  organism  were 
demonstrable in the patient's serum. 
In contrast to the polysaccharides, the so-called nucleoprotein frac- 
tion of the Pneumococcus evoked a delayed response which reaches its 
height in 24 hours.  It simulated in appearance the tuberculin reaction. 
The protein reaction generally appeared first early in convalescence 
and tended to become progressively more marked during the course of 
recovery.  Circulating antibodies for the nucleoprotein were present 
in  approximately equal  concentrations  during the periods of acute 
illness and recovery.  The protein reaction bore no  specific relation 
to the type of Pneumococcus producing the infection. 
The present report includes further observations on cutaneous re- 
actions to pneumococcus fractions and deals especially with the appear- 
ance of antibodies for more than  one specific type of  Pneumococcus 
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in  the  serum  of convalescent  patients.  The  individuals  whose sera 
presented these unusual reactions had  received repeated intradermal 
injections  of  the  pneumococcus  carbohydrates.  The  possible  rela- 
tionships between the repeated injection of the specific substances and 
the antibody formation will be  discussed. 
Materials  and Methods 
A.  Skin  Test  Materials 
1.  Type-Specific Capsular Potysacckarides.--The type-specific polysacchaxides 
were obtained in purified form from Types I, II and III Pneumococcus  by the 
method of Heidelberger  and Avery (2).  They are chemically  and serologically 
distinct and have been  identified  with the capsular material  of the cell.  The 
Type II and Type III polysaccharides  are nitrogen-free;  that of Type I contains 
5 per cent nitrogen as part of the sugar molecule (3).  The pol)/saccharides were 
diluted in physiological salt solution  to a concentration of 1:10,000 and 0.1 cc. 
containing 0.01 rag. of the specific soluble  substance was injected intracutane- 
ously.  Skin tests were  repeated  at  intervals  throughout the  disease  and  con- 
valescence. 
2. Nudeoprotein.--The  nucleoprotein  was prepared by the method of Avery 
and Morgan (4)  from an R  strain  derived  from a  Type II S  organism.  The 
material was standardized on the basis of nitrogen content and 0,01 rag. of protein 
in 0.1 cc. of physiological saline was used in all tests.  These tests were repeated  at 
approximately weekly intervals during the patient's stay in hospital. 
B.  Titration  of Sera  for  Antibodies 
At intervals during the acute illness and convalescence samples of serum were 
obtained and tested for the presence or absence of circulating antibodies. 
1.  Type-Specific Antibodies.--The  presence in the serum of type-specific anti- 
bodies was determined  by (a) agglutination,  and (b) passive protection of mice. 
a.  Type-Specific Agglutinins.----0.5 co. of varying dilutions  of the serum  to be 
tested was mixed with 0.5 co. of a heat-killed suspension of type-specific pneumo- 
cocci.  Final readings  were made after the mixtures had been incubated for 2 
hours in the water bath and then placed in the ice box overnight. 
b. Passive Protection of Mice.--The capacity of patient's serum to protect mice 
against infection was tested by the usual technique.  0.2 cc. of serum diluted  to 
0.5 cc. with salt solution was employed.  So far as possible each serum was tested 
against pneumococci of Types I, II and III.  The cultures used were invariably 
fatal for mice in doses of 0.0000001 cc. 
2. Antibodies for  Nudeoprotein.--Antibodies  for the nudeoprotein material 
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A  study of the cutaneous response to the injections  of the type- 
specific polysaccharides of the Pneumococcus and of the occurrence of 
circulating antibodies has been made in 74 cases of lobar pneumonia. 
The results confirm earlier observations and may be briefly summarized 
as follows:  Positive reactions were elicited only with the homologous 
polysaccharide  at  crisis  or  shortly  thereafter;  homologous  type- 
specific antibodies were demonstrable in the serum of each reactive 
patient.  In  no instance was a  positive skin reaction to  a  polysac- 
charide obtained in the absence of circulating antibodies for the type 
of Pneumococcus from which the polysaccharide was derived.  Table 
TABLE l 
The Incidence of Cutaneous Reactions to the Homologous Polysaccharide in  Con- 
valescent Patients 
Type of infecting orgsnism  No. patients  No. positive reaction  Per centreactionsgiVlng  positive 
21  21  100 
I IIII  17  10  58.8 
9  4  44.4 
13 recovered cases of Group IV--no reactions to polysaccharides of Types I, 
II, III. 
5 recovered cases of Type II (atypical)--no reactions to polysaccharides of 
Types I, II, III. 
9 fatal cases of various types--no reactions to polysaccharides of Types I, 
II, III. 
I shows the relative frequency of positive reactions to the homologous 
type of polysaccharide in patients convalescent from Type I, II or III 
pneumonia.  All but 4 of the  Type I  cases were treated  with anti- 
pneumococcus Type I serum. 
From Table I  it can be seen that positive cutaneous reactions were 
obtained in all of the Type I cases and in approximately 50 per cent of 
the Types II and III  patients.  The polysaccharides of Types I, II 
and III elicited no response in the 13  Group IV and the 3  atypical 
Type II patients.  The absence of reactivity in the 9 fatal cases agrees 
with earlier experiences in  that in  patients  with  lethal termination 
no reaction was obtained.  12  patients  convalescent from Type II 
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would be expected since their sera contained no circulating antibodies; 
the sera of the remaining 4 patients contained circulating antibodies 
but  no  reaction  to  the  polysaccharide occurred.  Thus, of  the  en- 
tire  group of patients  included in Table  I  a  positive  skin reaction 
was expected in 39 by virtue  of the fact  that they were  recovered 
cases of Type I, II or III infection whose sera contained type-specific 
antibodies.  Positive reactions were obtained in 35 of them. 
The cutaneous response to the nucleoprotein fraction of the Pneumo- 
coccus was studied in  the same group  of  cases.  The results have 
confirmed the validity of the earlier  conclusions.  The delayed pro- 
tein reaction appeared  first during convalescence.  The reactivity of 
the patient did not appear to be influenced by the titer of circulating 
antibodies for the protein fraction. 
Occurrence of Antibodies to  Heterologous Types  of Pneumococcus 
Other observers have repeatedly demonstrated the  occurrence of 
circulating antibodies for the homologous type of Pneumococcus at or 
about  the  time of crisis.  The present investigation  confirms these 
results and, in addition, discloses the fact that at the time when type- 
specific antibodies are  first  demonstrable in  the  blood  the  patient 
becomes reactive to the cutaneous injection of the homologous type- 
specific polysaccharide.  The reactions have been specifically limited 
to the homologous types.  In the present study repeated tests were 
made with the type-specific polysaccharides of Types  I,  II and III 
with a  view to  determining the length of time through which the 
reactive capacity might persist.  In  view of  the fact  that positive 
results at the time of recovery were strictly limited to the homologous 
type, it was rather surprising to observe after  repeated  tests that a 
positive skin reaction was obtained in certain instances with a polysac- 
charide of  heterologous type as  well.  With the appearance of the 
skin reaction to the heterologous polysaccharide,  circulating antibodies 
for the heterologous type of Pneumococcus were demonstrable in the 
patient's serum, in addition to those for the homologous type.  The 
chief interest in this report, therefore, is concerned with the develop- 
ment of specific antibodies for more than one type of Pneumococcus 
in patients who have repeatedly  received  intradermal injections of 
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characterized by the fact that they were heterologous in type to that 
of the  infecting  organism  and  were not  demonstrable  at  crisis  but 
appeared  1 to 3  weeks after the patient's  recovery.  These features 
were disclosed as a result of what at first appeared to be a  discrepancy 
in  specificity of  the  cutaneous  reaction.  The  results  can  be  more 
clearly brought out by describing in detail the course of events in  one 
patient. 
M. A., a girl of 14 years, suffering from Type II pneumonia was admitted on the 
second  day  of disease.  No circulating  antibodies  were  demonstrable  in  the 
patient's serum at this time.  Crisis  occurred on the tenth day.  On the thirteenth 
day skin tests with the polysaccharides of Types I, II and III revealed a positive 
reaction only to the Type II material.  The serum taken shortly thereafter con- 
tained circulating antibodies for Type II Pneumococcus alone.  8 days after the 
first test the skin testswere repeated and at this time positive reactions occurred 
both to Type II and Type I polysaccharides.  At this time her serum contained 
antibodies for Type I as well as for Type II Pneumococcus.  (See  Chart  1.) 
Because of the appearance of heterologous antibodies and  skin re- 
actions  a  series  of patients  was studied  in  order  to  determine  the 
frequency  with  which  the  phenomenon  occurred.  Skin  tests  and 
antibody determinations were made at varying intervals in 18 patients. 
Of these, 3 were cases of Type I pneumonia,  7 of Type II, 3 of Type III 
and 5 of Group IV.  At or about the time of crisis  antibodies for the 
homologous type of Pneumococcus appeared in all but 2 of the Types I, 
II and III patients.  In the  Group IV cases tests  were  not  carried 
out with  the  homologous organism.  However, in  no instance  were 
heterologous antibodies demonstrable at that time.  As convalescence 
progressed,  repetition of  skin  tests  and  antibody  determinations 
revealed that there had  developed, since they were previously absent, 
specific antibodies and a positive skin reaction  for at least one of the 
heterologous types of Pneumococcus.  Table II shows the intervals 
between the appearance  of homologous and heterologous antibodies 
in relation to the day of disease and recovery. 
From Table II it can be seen that in 10 of the  18 patients heterolo- 
gous  antibodies  were  detected  during  convalescence;  in  3  Type I 
patients,  4  Type II,  2 Type III,  and  1 of  Group IV.  In the great 
majority of cases the presence of circulating antibodies for the heterol- 
ogous type was first indicated by a positive skin test  to  the  polysac- 578  CUTANEOUS  REACTIONS  IN  PNEUMONIA 
TABLE II 
Differences in Time of Appearance of Homologous and Heterologous Antibodies in 
Patients Receiving Skin Tests with Type-Spec ~c Polysaccharides 
Patient 
Antibodies to homologous 
type 
Type  Day observed 
b. H. (serum), No. 7165 .....  I  3 
M. P. (serum), No. 7263 .....  I  8 
F. R., No. 7253..  I  9 
M. C., No. 7183  II  14 
G. M., No. 7248.  II  I0 
g. C., No. 7269..  II  11 
M. A., No. 7261  II  15 
~I. R., No. 7262..  III  6 
K. R., No. 7143..  III  5 
~. P., No. 7211.  IV  Not determined 
~i. C., No. 7189.  II  15 
[. S., No. 7195...  II  9 
5. Q., No. 7225.  II  0 
[. F., No. 7171...  III  0 
3. B., No. 7178... 
g. F., No. 7256. 
IV  Not determined  r. R., No. 7197... 
3. R., No. 7236. 
Antibodies to heterologous 
types 
Type 
II 
i  II 
II 
0 
0 
0 
io 
0 
III 
III 
0 
0 
0 
0 
II 
Daypt 
Day  cnsls 
oh- 
served 
17  6 
14  5 
22  7 
19  5 
19  9 
18  9 
22  10 
19 
26  8 
21  4 
26 
44  7 
8 
6 
7 
10 
8 
9 
5 
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charide  of  that  type.  The  type  of  Pneumococcus  for  which 
heterologous antibodies developed was in 7 instances Type I, in 4 Type 
II, and in 2 Type III.  In 3 cases specific antibodies for 2 heterologous 
types appeared.  Although the homologous antibodies  were detecta- 
ble at the time of crisis, those for heterologous types were usually noted 
in the second week of convalescence, the earliest being 9 days after 
recovery, the latest 37 days after recovery.  The period of time during 
which  antibodies were  detectable in  the serum and  skin reactivity 
remained positive varied from a few days to several months. 
These observations led to the hypothesis that the mechanism involved 
in the production of antibodies for heterologous types of Pneumococcus 
was associated with the intradermal inoculations of the type-specific 
TABLE nI 
The Incidence of Type-Specific Antibodies in the Control Series of Patients 
Type of infecting organism 
I 
II 
III 
Group IV 
No. cases  Antibodies for homologous 
type of Pneumococcus 
5 
6 
2 
Not determined 
Antibodies  for heterolo- 
gous types of Pneumo- 
¢occli$ 
I* 
1" 
0 
1"* 
* Type III antibodies present during disease and recovery. 
** Type II antibodies present during disease and recovery. 
polysaccharides.  In order to obtain  more information on this point 
the next 21 pneumonia patients admitted to hospital were studied as 
controls.  In this series no injections of the specific polysaccharides 
were made but the serum was tested at intervals for circulating type- 
specific antibodies  to  Pneumococcus Types I,  II  and  III.  In  the 
Group IV cases tests were not made for antibodies reactive with the 
infecting organism.  In most of the 21  cases homologous antibodies 
were observed at the time of recovery.  However, in striking contrast 
to the group of patients which had received repeated injections of the 
specific soluble substance, no patient in the control series  developed 
antibodies  for a  heterologous type.  In  only 3  patients  (I  each of 
Types I, II and Group IV) antibodies for a type other than that of the 
infectious agent were observed.  In these three instances the presence 580  CUTANEOUS  REACTIONS  IN  PNEUMONIA 
of the heterologous antibodies was detected in low titre early in  the 
acute illness and the concentration of the antibodies did not increase 
during convalescence.  They, therefore, bear no apparent relation to 
the present infection but are presumably attributable to a preexisting 
state.  This interpretation is substantiated by the fact that some nor- 
real individuals possess in their serum type-specific antibodies. 
Table III presents the distribution of the types of Pneumococcus  in 
the control group of  patients and the number in whom circulating 
antibodies were detectable. 
The 21 patients who served as controls were comparable to the test 
group with regard to age incidence, distribution of types of infecting 
Pneumococcus, severity of the infection and period of observation. 
The patients in whom heterologous antibodies were observed, re- 
ceived injections of 0.01  nag. of  the type-specific  capsular polysac- 
charides  derived from the  Pneumococcus of  Types  I,  II  and  III. 
The average number of injections before the appearance of antibodies 
for the corresponding  type of Pneumococcus  was three.  In 3 cases the 
antibodies were detected after a  single injection.  The largest total 
amount which was followed by heterologous antibody production was 
0.05  rag. whereas in other cases heterologous antibodies did not de- 
velop even after the injection of as  much as 0.08 rag. of the polysac- 
charides.  These  irregularities  demonstrate  the  fact  that  the 
production of antibodies is not solely dependent upon the quantity of 
polysaccharides injected.  The  average  time between the last injec- 
tion and the appearance of the antibodies was 6 to  10 days but in one 
case  they were first detected  20 days  after the last injection.  The 
exact data  regarding the individual patients in whom antibodies for 
heterologous  types  of  Pneumococcus  developed  are  presented  in 
graphic form in composite charts.  These charts show in relation to the 
day of disease, the time of appearance of type-specific agglutinins and 
mouse protective antibodies for homologous and heterologous types 
of Pneumococcus, the time, number and results of skin tests with the 
3 type-specific polysaccharides and the period during which the obser- 
vations were continued. 
DISCUSSION 
The primary interest of the present work centers in a  group of 18 
cases of lobar pneumonia 10 of whom, in convalescence, developed THOMAS  FRANCIS~  JR.~  AND  WILLIAM  S.  TILLETT  581 
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circulating antibodies for at least one type of Pneumococcus heterolo- 
gous to that etiologically related to the disease.  All of the patients in 
whom the phenomenon  was  observed had received repeated intra- 
dermal injections of 0.01 rag. of specific capsular polysaccharide from 
each  of  Types  I,  II  and  III  Pneumococcus.  Antibodies  for  the 
homologous type  of  Pneumococcus appeared  at  about  the  time of 
crisis.  Antibodies for heterologous types, on the other hand, appeared 
usually in the  second week of convalescence after 1 to 5 injections of 
the respective polysaccharides. 
A  control group of patients,  21 in number, received no skin  tests. 
Their sera, in the great majority of instances, contained antibodies for 
the homologous type of Pneumococcus.  In 3 of these cases antibodies 
for  a  heterologous  type were present  but  the  time  of  appearance 
differed from that of the antibodies observed in the first group in that 
they were detectable in low concentration not only in convalescence 
but during the acute illness as well.  Nor was any increase in concen- 
tration observed during convalescence.  Antibodies  to  the heterolo- 
gous  types  which  were  encountered in  these  3  cases,  apparently 
preexisted and their appearance is presumably unrelated to any inci- 
dent occurring in the course of the present infection.  The validity of 
this supposition is borne out by the fact that  type-specific antibodies 
may be found in the serum of certain normal individuals, who give no 
history of lobar pneumonia.  But, in no case were heterologous anti- 
bodies first detected in convalescence unless the patient had previously 
received intradermal injections of the type-specific polysaccharides. 
Many investigators have noted  the presence of specific  antibodies 
for the homologous strain or type of Pneumococcus in  the blood of 
pneumonia patients at the time of crisis.  Bacteriotropins  (5,  6,  7), 
agglutinins  (5,  7, 8, 9,  10,  11,  12)  and protective  antibodies (13,  14, 
15, 6, 12) have all been demonstrated but so far as can be discovered, 
in no instance has the development of antibodies for  a  heterologous 
type been described.  Chickering (11)  in  1914 followed the course of 
agglutinin production to all types throughout convalescence in 40 cases 
but found only antibodies for the  homologous type.  Clough  (7)  in 
1919,  using the serum of patients convalescent from pneumonia due 
to  known  types  of  Pneumococcus,  obtained  similar  results  with 
phagocytic and  agglutination reactions.  In  the  sera of  25  normal THOMAS FRANCIS~ JR.~ AND  WILLIAM  S.  TILLETT  583 
individuals, however,  Clough  (16)  found protective  antibodies  for 
Type I in 4 of 18 tests, for Type II in 8 of 18 tests; and of 19 tests for 
Type III antibodies, 8 were positive.  Ward (20) tested the capacity 
of the defibrinated blood of normal individuals to inhibit the growth 
of pneumococci of Types I, II and III.  In each instance a variable 
degree of pneumococcidal action was observed against one or more 
types of the organism.  Furthermore, this property was present  in 
the blood of patients early in the course of pneumonia even against 
the type of Pneumococcus producing the infection.  Robertson and 
Cornwell  (21),  employing  serum-leucocyte  mixtures  from  normal 
human beings, found that the blood of all persons tested by this method 
possessed pneumococcidal properties for at least one type of Pneumo- 
coccus and in the majority of instances for two or more types. 
In evaluating the factors involved in the production of antibodies 
for types of Pneumococcus heterologous to that causing the infection 
several possible mechanisms may be considered. 
It is possible that antibodies for other types were present before the 
onset of disease and were masked during the acute infection only to 
return  with  convalescence.  Or  that,  present  in  minimal amounts 
before the disease, the infection served to cause an outpouring of anti- 
bodies in  detectable  concentrations,--the anamnestic reaction  first 
observed by Cole (17). 
Interconvertibility of types as described by Griffith  (18)  and later 
studied by Dawson  (19)  offers a  possible  explanation.  One  might 
assume that with the development of type-specific antibodies to  the 
homologous organism a  change of type occurred and,  as  a  result, 
antibodies to the secondary type appeared. 
The evidence presented in this report implicates the polysaccharides 
employed  in intracutaneous tests and suggests that they were antigenic. 
On  the  basis  of  this  assumption, the  conditions  under  which the 
investigation was carried out may have favored antibody production. 
No previous data are available regarding the antigenicity in humans 
of the  purified type-specific polysaccharides of the  Pneumococcus. 
On the basis of animal experiments in this laboratory these substances, 
in the pure state, are considered non-antigenic.  It is  possible, how- 
ever, that in the process of recovery from infection, a highly reactive 
state exists in the human organism which responds to stimuli otherwise 584  CUTANEOUS  REACTIONS IN PNEUMONIA 
ineffective.  In the removal of the inflammatory material from its 
focus in the lungs, as takes place in pneumonic  resolution, the absorbed 
material may act as an adjunct to the polysaccharides (the "Schleppe" 
of the German investigators) forming a combination possessing anti- 
genic properties.  The polysaccharides which, under ordinary condi- 
tions, are haptens, may then acquire antigenic properties and determine 
the specificity of the antibodies produced.  It is of course also possible 
that the particular preparations used in this study, although they were 
prepared with great care, still contained minute amounts of combined 
polysaccharides. 
At present it is impossible to offer any final statement as to the exact 
mechanism by which antibodies  for the heterologous types are pro- 
duced.  Further work is  being carried on  with normal individuals 
and patients in an attempt more completely to elucidate the factors 
which play a r61e in the development  of these heterologous antibodies. 
SUMMARY 
The  majority  of patients  convalescent  from  pneumonia due  to 
Types I, II and III  Pneumococcus develop at the time of recovery 
circulating antibodies for the homologous type of organisms.  At the 
same time an immediate wheal  and erythema reaction  followed the 
intradermal  injection  of  the  homologous type-specific  polysaccha- 
ride in  100 per cent of Type I  patients, 58.8 per cent of Type II pa- 
tients, and 44 per cent of Type III patients. 
In a group of 18  patients repeatedly tested  with the type-specific 
polysaccharides, 10 developed in the second or third week of convales- 
cence circulating antibodies for one or more heterologous types.  In 
none of 21 control patients was this phenomenon observed. 
It is suggested that the development of circulating antibodies for 
heterologous types of Pneumococcus was associated with the previous 
intradermal injections of the type-specific polysaccharides. 
BIBLIOGRAPHY 
1.  Tillett, W. S., and Francis, T., Jr., J. Exp. ged., 1929, 50, 687. 
2.  Heidelberger, M., and Avery, O. T., J. Exp. Med., 1923, 38, 73. 
3. Heidelberger, M., Goebel, W. F., and Avery, O. T., J. Exp. Med., 1925,42, 727. 
4. Avery, O. T., and Morgan, H. J., J. Exp. Med., 1925, 42,347. THOMAS FRANCIS~ JR.~ AND  WILLIAM S.  TILLETT  585 
5. Lister, F. S., Publications  of South African Institute for Medical  Research, 
1913, No. 2. 
6.  Clough, P. W., Bull. J. Hopkins Hosp., 1913, 24~ 295. 
7.  Clough, P. W., Bull. ]. Hopkins Hosp., 1919, 30~ 167. 
8. Besangon, F., and Griffon, V., Ann. de !'Inst. Past., 1900, 14~ 449. 
9. Neufeld, F., Ztschr.f. Hyg. u. Infect.,  1902, 40~ 68. 
10.  Gargano, C., and Fattori, C., Riv. crit. di din. reed., 1903, 4, 177, 193. 
11.  Chickering, H. T., J. Exp. Med., 1914, 20~ 599. 
12. Lord, F. T., and Nesche, G. E., 3. Exp. Med., 1929, 50~ 449. 
13. Klemperer, G., and Klemperer, F., Berl. klin. Wchnschr., 1891,28~ 833. 
14. Neufeld, F., and HAndel, L., Arb. a. d. k. Gesundheitsamte, 1910, 34~ 166, 293. 
15. Dochez, A. R., J. Exp. Med., 1912,16~ 665. 
16.  Clough, P. W., J. Am. Med. Assoc., 1919, 731 785. 
17. Cole, R., Zeit. f. Hyg., 1904, 46~ 371 
18.  Griffith, F., 3". Hygiene, 1928, 47~ 577. 
19. Dawson, M. H., J. Exp. Med., 1930, 51~ 99, 123. 
20.  Ward, H. K., J. Exp. Med.,  1930, 51~ 675. 
21. Robertson, O. H., and Cornwell, M. A., J. Exp. Med.,  1930, 52~ 267. 